QQQ   432.61 (+0.36%)
AAPL   169.88 (-1.63%)
MSFT   417.18 (+0.86%)
META   502.36 (+0.43%)
GOOGL   155.37 (+0.33%)
AMZN   184.05 (+0.23%)
TSLA   156.63 (-3.00%)
NVDA   878.34 (+2.13%)
AMD   163.80 (+2.17%)
NIO   3.88 (-0.26%)
BABA   69.98 (-0.91%)
T   16.05 (-1.17%)
F   12.20 (-0.25%)
MU   121.93 (+0.46%)
GE   156.83 (+2.04%)
CGC   6.84 (-2.01%)
DIS   114.18 (+1.09%)
AMC   2.79 (+12.96%)
PFE   25.85 (-0.23%)
PYPL   63.89 (+0.60%)
XOM   118.94 (-0.62%)
QQQ   432.61 (+0.36%)
AAPL   169.88 (-1.63%)
MSFT   417.18 (+0.86%)
META   502.36 (+0.43%)
GOOGL   155.37 (+0.33%)
AMZN   184.05 (+0.23%)
TSLA   156.63 (-3.00%)
NVDA   878.34 (+2.13%)
AMD   163.80 (+2.17%)
NIO   3.88 (-0.26%)
BABA   69.98 (-0.91%)
T   16.05 (-1.17%)
F   12.20 (-0.25%)
MU   121.93 (+0.46%)
GE   156.83 (+2.04%)
CGC   6.84 (-2.01%)
DIS   114.18 (+1.09%)
AMC   2.79 (+12.96%)
PFE   25.85 (-0.23%)
PYPL   63.89 (+0.60%)
XOM   118.94 (-0.62%)
QQQ   432.61 (+0.36%)
AAPL   169.88 (-1.63%)
MSFT   417.18 (+0.86%)
META   502.36 (+0.43%)
GOOGL   155.37 (+0.33%)
AMZN   184.05 (+0.23%)
TSLA   156.63 (-3.00%)
NVDA   878.34 (+2.13%)
AMD   163.80 (+2.17%)
NIO   3.88 (-0.26%)
BABA   69.98 (-0.91%)
T   16.05 (-1.17%)
F   12.20 (-0.25%)
MU   121.93 (+0.46%)
GE   156.83 (+2.04%)
CGC   6.84 (-2.01%)
DIS   114.18 (+1.09%)
AMC   2.79 (+12.96%)
PFE   25.85 (-0.23%)
PYPL   63.89 (+0.60%)
XOM   118.94 (-0.62%)
QQQ   432.61 (+0.36%)
AAPL   169.88 (-1.63%)
MSFT   417.18 (+0.86%)
META   502.36 (+0.43%)
GOOGL   155.37 (+0.33%)
AMZN   184.05 (+0.23%)
TSLA   156.63 (-3.00%)
NVDA   878.34 (+2.13%)
AMD   163.80 (+2.17%)
NIO   3.88 (-0.26%)
BABA   69.98 (-0.91%)
T   16.05 (-1.17%)
F   12.20 (-0.25%)
MU   121.93 (+0.46%)
GE   156.83 (+2.04%)
CGC   6.84 (-2.01%)
DIS   114.18 (+1.09%)
AMC   2.79 (+12.96%)
PFE   25.85 (-0.23%)
PYPL   63.89 (+0.60%)
XOM   118.94 (-0.62%)
Free Trial

Eagle Pharmaceuticals (EGRX) Stock Forecast & Price Target

→ Your eBook: Mastering Earnings Announcements Trading (From StockEarnings) (Ad)
Free EGRX Stock Alerts
$4.69
-0.51 (-9.81%)
(As of 02:55 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Eagle Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Strong Sell
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$17.00
262.47% Upside
High Forecast$17.00
Average Forecast$17.00
Low Forecast$17.00
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Strong Sell
Strong Sell
Strong Sell
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
 N/A
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
 N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
 N/A
Consensus Price Target$17.00$17.00$17.00$31.00
Predicted Upside262.47% Upside-20.82% Downside-20.82% Downside21.52% Upside
Get Eagle Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

EGRX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EGRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eagle Pharmaceuticals Stock vs. The Competition

TypeEagle PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
1.00
2.68
2.49
Consensus RatingStrong SellModerate BuyHold
Predicted Upside260.17% Upside1,013.72% Upside11.56% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/9/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeNeutral ➝ Underweight$26.00 ➝ $17.00-20.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:15 PM ET.

EGRX Price Target - Frequently Asked Questions

What is Eagle Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Eagle Pharmaceuticals stock is Sell based on the current 1 sell rating for EGRX. The average twelve-month price prediction for Eagle Pharmaceuticals is $17.00 with a high price target of $17.00 and a low price target of $17.00. Learn more on EGRX's analyst rating history.

Do Wall Street analysts like Eagle Pharmaceuticals more than its competitors?

Analysts like Eagle Pharmaceuticals less than other Medical companies. The consensus rating for Eagle Pharmaceuticals is Strong Sell while the average consensus rating for medical companies is Moderate Buy. Learn more on how EGRX compares to other companies.

Does Eagle Pharmaceuticals's stock price have much downside?

According to analysts, Eagle Pharmaceuticals's stock has a predicted downside of -20.82% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:EGRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Your eBook: Mastering Earnings Announcements Trading
StockEarnings
The only accurate crypto trading system I know …
Weiss Ratings
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
1970’s computer coder issues shocking A.I. warning
TradeSmith